{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fusion&page=22",
    "query": {
      "intervention": "Fusion",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1228,
    "total_pages": 123,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fusion&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fusion&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T19:00:04.783Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07285148",
      "title": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "EGFR Mutation",
        "Metastatic Lung Cancer",
        "MET Alteration"
      ],
      "interventions": [
        {
          "name": "ANS014004 + PLB1004",
          "type": "DRUG"
        },
        {
          "name": "ANS014004 + Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beijing Pearl Biotechnology Limited Liability Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 253,
      "start_date": "2026-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285148"
    },
    {
      "nct_id": "NCT00611208",
      "title": "A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Lymphomas",
        "T-cell Leukemia",
        "Sezary Syndrome",
        "Mycosis Fungoides",
        "Cutaneous T-cell Lymphoma (CTCL)"
      ],
      "interventions": [
        {
          "name": "A-dmDT390-bisFv(UCHT1)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Virogen Biotechnology Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2008-01",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-29",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611208"
    },
    {
      "nct_id": "NCT02257489",
      "title": "Phase 1 Study of ACE-083 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Musculoskeletal Diseases"
      ],
      "interventions": [
        {
          "name": "ACE-083",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 75 Years · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2014-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02257489"
    },
    {
      "nct_id": "NCT05267106",
      "title": "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Adult-type Diffuse Gliomas"
      ],
      "interventions": [
        {
          "name": "Pemigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 83,
      "start_date": "2022-05-20",
      "completion_date": "2024-12-17",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 32,
      "location_summary": "Beverly Hills, California • Duarte, California • Fullerton, California + 28 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267106"
    },
    {
      "nct_id": "NCT05698576",
      "title": "TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer",
        "Adverse Effects Surgery",
        "MRI",
        "Ultrasound",
        "Sexual Function Disturbances",
        "Urinary Incontinence",
        "Urinary Function Disorders",
        "Prostate Biopsy",
        "Ablation"
      ],
      "interventions": [
        {
          "name": "TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Urological Research Network, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "50 Years to 80 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2022-03-16",
      "completion_date": "2033-01-30",
      "has_results": false,
      "last_update_posted_date": "2023-01-26",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 1,
      "location_summary": "Hialeah, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05698576"
    },
    {
      "nct_id": "NCT03358719",
      "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Blasts 30 Percent or Less of Bone Marrow Nucleated Cells",
        "Chronic Myelomonocytic Leukemia",
        "High Risk Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Refractory Anemia"
      ],
      "interventions": [
        {
          "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-03-27",
      "completion_date": "2021-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03358719"
    },
    {
      "nct_id": "NCT00603811",
      "title": "Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Infection"
      ],
      "interventions": [
        {
          "name": "VAX102 [Flagellin.HuM2e]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VaxInnate Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-09",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-23",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Galveston, Texas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603811"
    },
    {
      "nct_id": "NCT01027364",
      "title": "Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Factor IX (rFIXFc)",
          "type": "DRUG"
        },
        {
          "name": "rFIX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 123,
      "start_date": "2009-12",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027364"
    },
    {
      "nct_id": "NCT04033432",
      "title": "sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents",
        "Metastatic Prostate Adenocarcinoma",
        "Progressive Disease",
        "Prostate Carcinoma Metastatic in the Bone",
        "Prostate Carcinoma Metastatic in the Soft Tissue",
        "PSA Progression",
        "Stage IVB Prostate Cancer AJCC v8",
        "Testosterone Less Than 50 ng/dL"
      ],
      "interventions": [
        {
          "name": "Recombinant EphB4-HSA Fusion Protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2019-09-20",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04033432"
    },
    {
      "nct_id": "NCT04060407",
      "title": "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "CD24Fc",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-15",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-10-22T19:00:04.783Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060407"
    }
  ]
}